SEC Form 4 · accession 0001127602-16-051064
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Executive Chairman · Director
Period of report
May 2, 2016
Accepted (ET)
May 4, 2016 · 2:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | May 2, 2016 | M | 100,000 | $16.395 | A | 4,119,727 | D | |
| Common StockF3 | May 2, 2016 | S | 51,018 | $87.3953 | D | 4,068,709 | D | |
| Common StockF4 | May 2, 2016 | S | 48,982 | $88.2561 | D | 4,019,727 | D | |
| Common Stock | holding | — | — | — | 0 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F2 | $16.395 | May 2, 2016 | M | 100,000 | D | — | Jan 22, 2017 | Common Stock | 100,000 | 700,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $86.81 to $87.81. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $87.82 to $88.75. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.